Navigation Links
Spectral announces first quarter 2009 results

TORONTO, May 14 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), a company focused on bringing to market a diagnostic and a therapeutic targeting severe sepsis, today announced its financial results for the first quarter ended March 31, 2009.

"This quarter, we achieved an important milestone by securing the exclusive rights to develop and commercialize Toraymyxin(TM) for the US market after thorough due diligence into the product and its potential market opportunity," said Dr. Paul Walker, President and CEO of Spectral. "Toraymyxin(TM) has been used on more than 70,000 patients to date, primarily in Europe and Japan, for the treatment of severe sepsis and has demonstrated a significant reduction in the mortality of patients with severe sepsis compared to standard of care. We believe that, when used together with our proprietary Endotoxin Activity Assay (EAA(TM)), Toraymyxin(TM) represents a significant medical advance in helping doctors manage a devastating disease. Our next steps will be to obtain an Investigational Device Exemption (IDE) from the US FDA and to initiate a registration trial for Toraymyxin(TM) in 2009."

    First quarter 2009 highlights:

    -   Data on the clinical utility of EAA(TM) and Toraymyxin(TM) was
        featured in a key scientific symposium entitled, "The Role of
        Endotoxin," that included presentations from six thought leaders in
        the field of sepsis, at the 29th International Symposium on Intensive
        Care and Emergency Medicine in Brussels, Belgium in March.

    -   New findings demonstrating the clinical utility of EAA(TM) were
        presented at the 13th Annual Critical Care for Endotoxemia Congress.
        The conference took place in Tokyo, Japan in February.

    -   A final license and supply agreement was signed with Toray
        Industries, Inc. for the exclusive development and commercial rights
        in the U.S. for Toraymyxin(TM) in March.

    -   A preliminary meeting was held with the US FDA.

Financial Review

For the three months ended March 31, 2009, Spectral reported sales of $842,000, compared to $664,000 for the corresponding period in 2008. This represents a 27% increase. Sales in all product categories were higher due to improved EAA(TM) diagnostic sales and the consistency of royalty revenues and reagent sales related to the Company's proprietary Troponin I products.

Operating expenses for the three months ended March 31, 2009 were $1,043,000, compared to $976,000 for the corresponding period in 2009, due to the continued maintenance of a low cost operating structure. These expenses included $100,000 of costs related to the development of the Toraymyxin(TM) clinical pathway.

For the three months ended March 31, 2009, the Company reported a loss of $404,000, or ($0.02) per share, compared to a loss of $448,000 or ($0.02) per share for the corresponding period in 2008.

Cash and short term investments as at March 31, 2009 totaled $4,053,000, compared to $4,297,000 as at December 31, 2008. Management expects that the Company will maintain a minimum cash and short term investment balance of $3,000,000 for the rest of 2009.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed to treat endotoxemia, Spectral is well-positioned to promote the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    Spectral Diagnostics Inc.

    Balance Sheets - unaudited
    As at March 31, 2009 and December 31, 2008

    (in thousands of dollars)
                                                            2009        2008
                                                               $           $

    Current assets
    Cash and cash equivalents                                 16         297
    Short-term investments                                 4,037       4,000
    Accounts receivable                                      908         860
    Inventories                                              204         203
    Prepaid expenses                                         168          42

                                                           5,333       5,402

    Property, plant and equipment                            449         493

    Commercial instruments                                   133         132

    Purchased technology and trademarks                      941       1,058

                                                           6,856       7,085

    Current liabilities
    Bank indebtedness                                        385           -
    Accounts payable and accrued liabilities                 332         540

    Deferred revenue                                         279         322

    Convertible notes payable                              2,213       2,172

                                                           3,209       3,034

    Shareholders' Equity

    Common shares                                          2,524       2,524

    Other equity                                           5,716       5,716

    Deficit                                               (4,593)     (4,189)

                                                           3,647       4,051

                                                           6,856       7,085

    Spectral Diagnostics Inc.

    Statements of Operations, Comprehensive Loss and Deficit - unaudited
    For the three months ended March 31, 2009 and 2008
    (in thousands of dollars, except share and per share data)

                                                            2009        2008
                                                               $           $

    Sales                                                    842         664

    Cost of sales                                            184         200

    Gross margin                                             658         464

    Operating expenses
    Selling, general and administrative                      891         792
    Amortization                                             164         154
    Foreign exchange gain                                    (32)         (5)
    Stock-based compensation                                   -          21
    Research and product development,
     net of tax credits                                       20          14

                                                           1,043         976

    Loss before the following                               (385)       (512)

    Interest expense on convertible notes payable            (41)        (41)

    Other net interest income                                 22         105


    Loss and comprehensive loss  for the period             (404)       (448)

    Deficit - Beginning of period                         (4,189)     (2,687)


    Deficit - End of period                               (4,593)     (3,135)

    Basic and diluted loss  per common share               (0.02)      (0.02)

    Weighted average number of common
     shares outstanding                               24,118,424  24,118,424

    Spectral Diagnostics Inc.

    Statements of Cash Flows - unaudited
    For the three months ended March 31, 2009 and 2008

    (in thousands of dollars)

                                                            2009        2008
                                                               $           $

    Cash provided by (used in)

    Operating activities
    Loss and comprehensive loss for the period              (404)       (448)
    Items not affecting cash
      Amortization                                           164         154
      Amortization of commercial instruments included
       in cost of sales                                       21           5
      Stock-based compensation expense                         -          21
      Interest on convertible notes payable                   41          41
    Changes in non-cash working capital                     (383)       (167)

                                                            (561)       (394)

    Investing activities
    Purchase of property, plant and equipment                 (3)        (14)
    Purchase of commercial instruments                       (22)        (22)
    Increase  in short-term investments                      (37)       (103)
    Decrease in deferred revenue                             (43)         (3)

                                                            (105)       (142)

    Financing activities
    Bank indebtedness                                        385           -

    Decrease in cash and cash equivalents
     during the period                                      (281)       (536)

    Cash and cash equivalents - Beginning of period          297         638

    Cash and cash equivalents - End of period                 16         102

SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... SAN DIEGO , Nov. 24, 2015 Halozyme Therapeutics, ... Jaffray Healthcare Conference in New York on ... Dr. Helen Torley , president and CEO, will provide a ... New York at 1:00 p.m. ET/10:00 a.m. ... communication and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
(Date:10/26/2015)... 26, 2015  Delta ID Inc., a company focused ... and PC devices, announced its ActiveIRIS® technology powers the ... F-02H launched by NTT DOCOMO, INC in ... second smartphone to include iris recognition technology, after a ... F-04G in May 2015, world,s first smartphone to have ...
Breaking Biology News(10 mins):